• 1. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543
• 2. An all-solid-state asymmetric device based on a polyaniline hydrogel for a high energy flexible supercapacitor?
  Hamid Heydari,Mohammad B. Gholivand New J. Chem., 2017,41, 237-244
• 3. An artificial photosynthesis system comprising a covalent triazine framework as an electron relay facilitator for photochemical carbon dioxide reduction?
  Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200
• 4. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 5. An aptasensor for the detection of ampicillin in milk using a personal glucose meter
  Xixi Li,Nanwei Zhu,Ruohan Li,Qinpu Zhang Anal. Methods, 2020,12, 3376-3381

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Keto acids and derivatives Beta-keto acids and derivatives

Recent Advances in the Application of Ethyl 2-(Ethoxymethylene)-4,4,4-Trifluoro-3-Oxobutanoate (CAS: 1048670-08-1) in Chemical Biology and Pharmaceutical Research

Ethyl 2-(ethoxymethylene)-4,4,4-trifluoro-3-oxobutanoate (CAS: 1048670-08-1) is a fluorinated β-keto ester derivative that has garnered significant attention in recent years due to its versatile applications in chemical biology and pharmaceutical synthesis. This compound serves as a key intermediate in the preparation of various heterocyclic compounds, particularly those with potential biological activities. Recent studies have explored its utility in the synthesis of trifluoromethyl-substituted pyrazoles, isoxazoles, and other nitrogen-containing heterocycles, which are of great interest in drug discovery programs targeting inflammation, cancer, and infectious diseases.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the compound's effectiveness as a building block for the synthesis of novel trifluoromethylated pyrazole derivatives with potent COX-2 inhibitory activity. The researchers utilized ethyl 2-(ethoxymethylene)-4,4,4-trifluoro-3-oxobutanoate as a starting material in a one-pot cyclocondensation reaction with hydrazine derivatives, achieving excellent yields of the target compounds. Molecular docking studies revealed that the trifluoromethyl group significantly enhanced binding affinity to the COX-2 active site, suggesting potential for developing new anti-inflammatory agents.

In the field of antimicrobial research, a recent publication in Bioorganic & Medicinal Chemistry Letters (2024) reported the use of this compound in the synthesis of novel quinolone derivatives with enhanced activity against drug-resistant bacterial strains. The presence of the trifluoromethyl group was found to improve membrane permeability and target binding, while the ethoxymethylene moiety contributed to metabolic stability. These findings highlight the compound's potential in addressing the growing challenge of antibiotic resistance.

From a synthetic chemistry perspective, advances in catalytic methods have improved the efficiency of reactions involving ethyl 2-(ethoxymethylene)-4,4,4-trifluoro-3-oxobutanoate. A 2023 study in Advanced Synthesis & Catalysis described a novel copper-catalyzed coupling reaction that enables the direct functionalization of this compound at the β-position, opening new avenues for structural diversification. This methodological breakthrough has significant implications for medicinal chemistry, allowing for more efficient exploration of structure-activity relationships in drug discovery programs.

Ongoing research continues to explore the full potential of this versatile building block. Current investigations focus on its application in the synthesis of PROTACs (proteolysis targeting chimeras) and other targeted protein degradation technologies, where the trifluoromethyl group may offer advantages in terms of protein binding and pharmacokinetic properties. As the pharmaceutical industry increasingly embraces fluorine-containing compounds for their beneficial effects on drug properties, ethyl 2-(ethoxymethylene)-4,4,4-trifluoro-3-oxobutanoate is poised to play an important role in the development of next-generation therapeutics.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)